Nothing Special   »   [go: up one dir, main page]

DZ2186A1 - Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation. - Google Patents

Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.

Info

Publication number
DZ2186A1
DZ2186A1 DZ970032A DZ970032A DZ2186A1 DZ 2186 A1 DZ2186 A1 DZ 2186A1 DZ 970032 A DZ970032 A DZ 970032A DZ 970032 A DZ970032 A DZ 970032A DZ 2186 A1 DZ2186 A1 DZ 2186A1
Authority
DZ
Algeria
Prior art keywords
osteoporosis
preparation
treatment
pharmaceutical compositions
mixed pharmaceutical
Prior art date
Application number
DZ970032A
Other languages
English (en)
Inventor
Hua Zhu Ke
David D Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ2186A1 publication Critical patent/DZ2186A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
DZ970032A 1996-02-28 1997-02-26 Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation. DZ2186A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1241296P 1996-02-28 1996-02-28

Publications (1)

Publication Number Publication Date
DZ2186A1 true DZ2186A1 (fr) 2002-12-02

Family

ID=21754846

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970032A DZ2186A1 (fr) 1996-02-28 1997-02-26 Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.

Country Status (45)

Country Link
US (2) US6323232B1 (fr)
EP (3) EP1236475A3 (fr)
JP (2) JPH11504352A (fr)
KR (1) KR19990087337A (fr)
CN (5) CN1515317A (fr)
AP (3) AP974A (fr)
AR (2) AR005987A1 (fr)
AT (1) ATE405273T1 (fr)
AU (1) AU703285B2 (fr)
BG (1) BG64582B1 (fr)
BR (1) BR9612533A (fr)
CA (1) CA2247420C (fr)
CL (1) CL2004000119A1 (fr)
CO (1) CO4761063A1 (fr)
CZ (1) CZ297452B6 (fr)
DE (1) DE69637651D1 (fr)
DK (1) DK0883404T3 (fr)
DZ (1) DZ2186A1 (fr)
ES (1) ES2312169T3 (fr)
GT (2) GT199700009A (fr)
HK (1) HK1018210A1 (fr)
HN (1) HN1996000101A (fr)
HR (1) HRP970118A2 (fr)
HU (1) HUP9904123A3 (fr)
ID (1) ID19886A (fr)
IL (3) IL154380A0 (fr)
IS (1) IS4812A (fr)
MA (1) MA26420A1 (fr)
NO (2) NO323648B1 (fr)
NZ (1) NZ323456A (fr)
OA (1) OA10837A (fr)
PE (2) PE20011302A1 (fr)
PL (2) PL187962B1 (fr)
PT (1) PT883404E (fr)
RU (1) RU2190395C2 (fr)
SI (1) SI0883404T1 (fr)
SK (1) SK118398A3 (fr)
TN (1) TNSN97040A1 (fr)
TR (1) TR199801679T2 (fr)
TW (1) TW464496B (fr)
UA (1) UA69372C2 (fr)
UY (1) UY24472A1 (fr)
WO (1) WO1997031640A1 (fr)
YU (1) YU7797A (fr)
ZA (1) ZA971719B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6531485B2 (en) 1997-06-23 2003-03-11 Pfizer Inc. Prostaglandin agonists
BR9811775A (pt) * 1997-09-09 2000-08-29 Procter & Gamble Método de aumento de volume ósseo
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP0950417A3 (fr) * 1998-02-23 2000-02-23 Pfizer Products Inc. Traitement d' anomalies du squelette
CN1303379A (zh) * 1998-06-03 2001-07-11 辉瑞产品公司 作为氧化氮合酶抑制剂的含稠环取代基的2－氨基吡啶
EP1085867A1 (fr) * 1998-06-16 2001-03-28 Pfizer Products Inc. Combinaisons therapeutiques de modulateurs (selectifs) des recepteurs des oestrogenes (serm) et de secretagogues d'hormones de croissance (ghs) pour traiter la fragilite musculo-squelettique
DE69916932T2 (de) 1998-06-16 2005-04-21 Pfizer Prod Inc Kombinationstherapeutika, enthaltend einen selektiven Östrogenrezeptormodulator und Prostaglandin E2
PE20000646A1 (es) * 1998-06-16 2000-08-05 Pfizer Prod Inc Terapia de combinacion para la fragilidad musculoesqueletica
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
EP1004306A3 (fr) * 1998-08-06 2000-06-07 Pfizer Products Inc. Agonistes/antagonistes de l'estrogène
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
BR9914998A (pt) * 1998-11-03 2001-07-10 Pfizer Prod Inc Antibióticos macrólidos
NZ513827A (en) * 1999-03-05 2001-09-28 Procter & Gamble Methods of increasing bone volume using non-naturally-occurring FP selective agonists and antiresorptive compounds
GB9913649D0 (en) * 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
EP1113007A1 (fr) * 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
RU2328276C2 (ru) * 2000-06-01 2008-07-10 Ватсон Фармасьютикалз, Инк. Трансдермальная доставка лазофоксифена
EP1192945A3 (fr) * 2000-09-21 2004-03-03 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter l'ostéoarthrite
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
ATE288303T1 (de) * 2000-11-30 2005-02-15 Pfizer Prod Inc Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel
WO2003011282A1 (fr) * 2001-07-31 2003-02-13 Pfizer Products Inc. Compositions pharmaceutiques, necessaires et methodes faisant intervenir des combinaisons d'agonistes/antagonistes des oestrogenes, d'oestrogenes et de progestines
AR042132A1 (es) 2002-11-26 2005-06-08 Smithkline Beecham Corp Compuesto de 2- hidroxi -3-(2- aril - 1, 1 - dimetiletilamino) propoxifenilo, composicion farmaceutica que lo comprende y uso del mismo para prepararla
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2849910A1 (fr) 2011-09-30 2013-04-04 Perio Sciences, Llc Compositions antioxydantes pour le traitement de l'inflammation ou de dommages oxydatifs
CN103142644B (zh) * 2013-03-21 2014-07-23 青岛正大海尔制药有限公司 骨化三醇和氟化钠的混悬颗粒及其制备方法
MX2019004184A (es) 2016-10-11 2019-09-27 Univ Duke Tratamiento con lasofoxifeno del cancer de mama.
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
WO2019204985A1 (fr) * 2018-04-24 2019-10-31 深圳华大生命科学研究院 Biomarqueur d'ostéoporose et utilisation associée
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
BE637389A (fr) 1962-09-13
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3927197A (en) 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US3982016A (en) 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4000309A (en) 1975-08-06 1976-12-28 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4097601A (en) 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4219483A (en) 1978-09-11 1980-08-26 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
EP0162510B1 (fr) 1984-04-30 1991-08-28 THE PROCTER & GAMBLE COMPANY Equipement pour le traitement de l'ostéoporose
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
GB2196003A (en) 1986-09-11 1988-04-20 Nat Res Dev Iodo-and bromo-tamoxifen derivatives
US5216183A (en) 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
EP0559751B1 (fr) 1990-11-26 1997-03-26 RECKER, Robert R. Traitement de l'osteoporose utilisant un facteur de liberation d'hormone de croissance (grf) combine a une hormone parathyroidienne (pth)
JPH04312526A (ja) 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
HUT72076A (en) 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (fr) 1993-07-22 1997-04-21 Lilly Co Eli
CA2173333A1 (fr) * 1993-10-19 1995-04-27 Barry J. Gertz Combinaison de biphosphonates et de secretagogues de l'hormone de croissance
PL322706A1 (en) 1993-11-09 1998-02-16 Merck & Co Inc Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
EP0730578A4 (fr) 1993-11-24 1997-10-08 Merck & Co Inc Composes contenant un groupe indolyle et leur utilisation pour favoriser la liberation d'hormones(s) de croissance
US5441966A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
WO1995034311A1 (fr) 1994-06-13 1995-12-21 Merck & Co., Inc. Compose de piperazine provoquant la liberation de l'hormone de croissance
JPH10505091A (ja) * 1994-09-09 1998-05-19 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症用のホスホネート及び副甲状腺ホルモン
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
IL120270A0 (en) 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US6100301A (en) 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
DK0904273T3 (da) 1996-05-07 2003-07-07 Pfizer Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist
BR9709499A (pt) 1996-05-31 1999-08-10 Novo Nordisk As Processo para prevenção ou tratamento de osteoporose e de perturbações relacionamas uso de um componente de hormónio do crescimento uso de uma composição com uma ação de anti-reabsorção sobre os ossos e produtos
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Also Published As

Publication number Publication date
HRP970118A2 (en) 1998-04-30
ID19886A (id) 1998-08-13
HN1996000101A (es) 1997-06-26
CO4761063A1 (es) 1999-04-27
OA10837A (en) 2001-08-13
SK118398A3 (en) 2000-07-11
JPH11504352A (ja) 1999-04-20
NO983936D0 (no) 1998-08-27
ZA971719B (en) 1998-08-27
CN1515317A (zh) 2004-07-28
IL154380A0 (en) 2003-09-17
CA2247420A1 (fr) 1997-09-04
BG102726A (en) 1999-04-30
NZ323456A (en) 2001-03-30
DE69637651D1 (en) 2008-10-02
EP0883404B1 (fr) 2008-08-20
DK0883404T3 (da) 2008-10-20
PL187219B1 (pl) 2004-06-30
SI0883404T1 (sl) 2008-10-31
GT199700009AA (es) 1999-01-23
HUP9904123A2 (hu) 2000-05-28
CL2004000119A1 (es) 2005-02-11
ATE405273T1 (de) 2008-09-15
IL125493A0 (en) 1999-03-12
AP975A (en) 2001-06-12
CA2247420C (fr) 2011-02-15
PL328831A1 (en) 1999-02-15
HUP9904123A3 (en) 2001-01-29
AR060853A2 (es) 2008-07-16
CN1242813C (zh) 2006-02-22
CN1515254A (zh) 2004-07-28
TW464496B (en) 2001-11-21
EP1236475A3 (fr) 2003-11-05
AP1179A (en) 2003-06-30
CN1209064A (zh) 1999-02-24
JP2002308771A (ja) 2002-10-23
TR199801679T2 (xx) 2001-06-21
CN1515316A (zh) 2004-07-28
CN1515258A (zh) 2004-07-28
EP0883404A1 (fr) 1998-12-16
AP974A (en) 2001-06-12
AP2002002661A0 (en) 2002-12-31
HK1018210A1 (en) 1999-12-17
WO1997031640A1 (fr) 1997-09-04
EP1932543A3 (fr) 2012-01-04
YU7797A (sh) 2000-10-30
NO20063853L (no) 1998-08-27
BG64582B1 (bg) 2005-08-31
AR005987A1 (es) 1999-07-21
PE20011302A1 (es) 2001-12-25
NO983936L (no) 1998-08-27
UY24472A1 (es) 2000-09-29
ES2312169T3 (es) 2009-02-16
US7255984B2 (en) 2007-08-14
MA26420A1 (fr) 2004-12-20
PE58998A1 (es) 1998-10-16
BR9612533A (pt) 1999-07-20
PT883404E (pt) 2008-11-14
PL187962B1 (pl) 2004-11-30
TNSN97040A1 (fr) 2005-03-15
EP1236475A2 (fr) 2002-09-04
KR19990087337A (ko) 1999-12-27
AU703285B2 (en) 1999-03-25
UA69372C2 (en) 2004-09-15
RU2190395C2 (ru) 2002-10-10
GT199700009A (es) 1998-07-10
US20010009920A1 (en) 2001-07-26
IS4812A (is) 1998-07-28
IL154379A0 (en) 2003-09-17
AU1039897A (en) 1997-09-16
AP2000001962A0 (en) 2000-12-31
NO323648B1 (no) 2007-06-18
CZ271898A3 (cs) 1999-06-16
CZ297452B6 (cs) 2006-12-13
US6323232B1 (en) 2001-11-27
AP9700934A0 (en) 1997-04-30
EP1932543A2 (fr) 2008-06-18

Similar Documents

Publication Publication Date Title
DZ2186A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
DZ2410A1 (fr) Dérivés d'acide arylsulfonylaminohydroxamique procédé pour leur préparation et compositions pharmaceutiques
DZ2666A1 (fr) Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2596A1 (fr) Associations pharmaceutiques d'amlodipine et d'atorvastatine et procédé pour leur préparation.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2600A1 (fr) Associations pharmaceutiques d'amlodipine et d'unestatine et procédé pour leur préparation.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2358A1 (fr) Amides inhibiteurs de sécrétion de apo b/mtp procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2420A1 (fr) Formulations nouvelles comprenant l'amoxycilline et du clavulanate et procédé pour leur préparation.
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
DZ2394A1 (fr) Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2675A1 (fr) Association pharmaceutique pour le traitement d'undysfunctionnement sexuel et compositions la conte nant.
DZ1958A1 (fr) Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.
DZ2414A1 (fr) 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2550A1 (fr) Dérivés d'azétidinylpropylpipéridine procédé pour leur préparation et compositions pharmaceutiques les contenant.
MC1915A1 (fr) Procédés pour la préparation de 2',3'-didésoxynucléosides et de formulations pharmaceutiques en contenant
DZ2155A1 (fr) Aazétidines, procédé pour leur préparation, et co mpositions pharmaceutiques les contenant.
DZ2709A1 (fr) Polysaccharides de synthèse procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2702660B1 (fr) Compositions thérapeutiques stabilisées et leur procédé de préparation.